<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03285815</url>
  </required_header>
  <id_info>
    <org_study_id>NCC 2016-0120</org_study_id>
    <nct_id>NCT03285815</nct_id>
  </id_info>
  <brief_title>Prostate Cancer - Localized Adenocarcinoma Proton Therapy</brief_title>
  <official_title>A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With a Localized Prostate Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With A Localized
      Prostate Adenocarcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For Proton therapy with prostate adenocarcinoma patients.

      Arm 1: Proton therapy 3CGE x 20days = Total 60 CGE for 4 weeks.

      Arm 2: Proton therapy 4.7CGE x 10days = Total 47 CGE for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BCFFS</measure>
    <time_frame>up to 5 years from a initial follow-up</time_frame>
    <description>To evaluate biochemical failure-free survival (BCFFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute/late toxicity (CTCAE v4.0)</measure>
    <time_frame>up to 5 years from a initial follow-up</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) V 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>up to 5 years from a initial follow-up</time_frame>
    <description>follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPIC (Extended Prostate Cancer Index Composite)</measure>
    <time_frame>up to 5 years from a initial follow-up</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Proton Therapy 60 CGE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 CGE (3CGE X 20) for 4wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proton Therapy 47 CGE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>47 CGE (4.7CGE X 10) for 2wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Proton Therapy</intervention_name>
    <arm_group_label>Proton Therapy 60 CGE</arm_group_label>
    <arm_group_label>Proton Therapy 47 CGE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0

          -  ECOG performance status:0-1

          -  Signed study specific informed consent prior to study entry.

        Exclusion Criteria:

          -  Postoperative residual or recurrent tumor

          -  Evidence of distant metastasis previous irradiation for the tumor in the same location

          -  Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwanho Cho</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kwanho Cho</last_name>
    <phone>82-31-920-1720</phone>
    <email>kwancho@ncc.re.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kwanho Cho</name>
      <address>
        <city>Ilsan</city>
        <state>Gyenggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwanho Cho</last_name>
      <phone>82-31-920-1720</phone>
      <email>kwancho@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Taehyun Kim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yeonjoo Kim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kanghyun Lee</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youngkyung Lim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaeyoung Jung</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byungho Nam</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>September 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Kwan Ho Cho</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

